Global Bioartificial Organ Manufacturing Market, By Degree of Automation (Semi-Automated, Fully Automated, Handworked), Materials (Mechanical, Biomechanical, Biological), Process (Architectural Predesign, Preparation of Materials and Construction Tools, Homogeneous/Heterogeneous Cell Assembling, Post Multi-Tissue Maturation) – Industry Trends and Forecast to 2030.
Bioartificial Organ Manufacturing Market Analysis and Size
Healthcare surgery treatment for patients with tissue loss or end-stage organ failure is becoming more common as the global population ages and pathologies limit or affect organ functionality progress. According to the American Transplant Foundation, there are approximately 114,000 people on the waiting list for organ transplantation, with approximately 20 deaths due to organ shortages. With such an increase in demand for organ transplants, the market is expected to expand significantly as bioartificial organs help to alleviate donor organ shortages.
Data Bridge Market Research analyses that the bioartificial organ manufacturing market which was USD 23.13 billion in 2022, is expected to reach USD 42.03 billion by 2030, at a CAGR of 7.75% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Bioartificial Organ Manufacturing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Degree of Automation (Semi-Automated, Fully Automated, Handworked), Materials (Mechanical, Biomechanical, Biological), Process (Architectural Predesign, Preparation of Materials and Construction Tools, Homogeneous/Heterogeneous Cell Assembling, Post Multi-Tissue Maturation)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
B. Braun SE (Germany), Boston Scientific Corporation (U.S.), Getinge AB. (Sweden), ABIOMED. (U.S.), Asahi Kasei Corporation (Japan), Berlin Heart (Germany), CARMAT (France), Jarvik Heart, Inc. (U.S.), Terumo Corporation (Japan), SynCardia Systems, LLC (U.S.), Nipro Europe Group Companies (Japan), Medtronic (U.S.), Organovo Holdings Inc. (U.S.), NexImmune (U.S.), Diabeloop SA (France), Admetsys (U.S.), Defymed (France), Pancreum, Inc. (U.S.), Beta Bionics Inc. (U.S.), Integra LifeSciences (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Bioartificial organ manufacturing technologies are a series of enabling techniques that can produce human organs based on bionic principles. Organ manufacturing technologies can be divided into three main groups: (1) fully automated, (2) semi-automated, and (3) handworked (or handmade). One of the most promising bioartificial organ manufacturing technologies is combining multi-nozzle three-dimensional printing techniques to assemble personal cells and other biomaterials to build exclusive organ substitutes for defective/failed human organs.
Global Bioartificial Organ Manufacturing Market Dynamics
Drivers
• Increased R&D activities
Factors such as increased product launches increased R&D activities, and key market players' strategies will drive the growth of the studied segment. Furthermore, the segment's growth is expected to be fuelled by new product approvals and ongoing government support. In February 2020, the U.S. Food and Drug Administration (FDA) granted Abbott Breakthrough Device designation for its in-development fully implantable left ventricular assist system. In March 2021, Penn State Health Milton S. Hershey Medical Center became the country's second hospital to implant a newly designed EvaHeart2 Left Ventricular Assist System (LVAS) in a patient with severe heart failure. These all are certain factors that propel the growth of the market.
• Increasing prevalence of organ failure
The rising prevalence of organ failure caused by severe infections, cardiovascular disease, and trauma increases the number of organ transplant surgeries. In 2019, the World Health Organization reported approximately 48.9 million cases of sepsis. Adopting bad habits like drinking and smoking leads to liver and heart failure. As the prevalence of such illnesses rises, so does the risk of organ failure, driving up demand for bioartificial organs.
Opportunities
• Advances in 3D bioprinting
Advances in 3D bioprinting have proven critical in organ transplantation because it is used to create artificial organs. 3D bioprinting is becoming increasingly popular because it reduces the risk of organ rejection. Furthermore, artificial intelligence is poised to alter global trends in artificial device usage. Many countries are currently focusing on a tool that provides a personalized assessment of organ and donor suitability. This tool will be extremely helpful in making informed decisions about organ retrieval and determining whether patients should accept donor organs or wait for better options.
Restraints/Challenges
- Side effects associated with artificial organs
Lack of skilled professionals, transplant side effects such as skin irritation, high procedure costs, low technology penetration in developing countries, and other factors are impeding the growth of the bioartificial organ market. The presence of the disease in the base tissue used to create the organ is a major concern. In such cases, the tissue may already be infected with another disease.
- High cost of artificial organs
The total cost of growing and transplanting an artificial organ is prohibitively expensive, limiting its application to the general public. There is a high risk of organ failure, and the body may require time to adjust to the new organ.
This bioartificial organ manufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bioartificial organ manufacturing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Bioartificial Organ Manufacturing Market Scope
The bioartificial organ manufacturing market is segmented on the basis of degree of automation, materials, and process. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Degree of Automation
- Semi- Automated
- Fully Automated
- Handworked
Materials
- Mechanical
- Biomechanical
- Biological
Process
- Architectural Predesign
- Preparation of Materials and Construction Tools
- Homogeneous/Heterogeneous Cell Assembling
- Post Multi-Tissue Maturation
Bioartificial Organ Manufacturing Market Regional Analysis/Insights
The bioartificial organ manufacturing market is analysed and market size insights and trends are provided by country, degree of automation, materials, and process as referenced above.
The countries covered in the bioartificial organ manufacturing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the bioartificial organ manufacturing market because of the region's well-developed healthcare infrastructure and favourable reimbursement policies.
Asia-Pacific is expected to grow at the highest rate in the forecast period of 2023 to 2030 owing to the rising aging population, and lack of organ donors.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The bioartificial organ manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for bioartificial organ manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bio-artificial organ manufacturing market. The data is available for historic period 2011-2021.
Competitive Landscape and Bioartificial Organ Manufacturing Market Share Analysis
The bioartificial organ manufacturing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bioartificial organ manufacturing market.
Some of the major players operating in the bioartificial organ manufacturing market are:
- B. Braun SE (Germany)
- Boston Scientific Corporation (U.S.)
- Getinge AB. (Sweden)
- ABIOMED. (U.S.)
- Asahi Kasei Corporation (Japan)
- Berlin Heart (Gemany)
- CARMAT (France)
- Jarvik Heart, Inc. (U.S.)
- Terumo Corporation (Japan)
- SynCardia Systems, LLC (U.S.)
- Nipro Europe Group Companies (Japan)
- Medtronic (U.S.)
- Organovo Holdings Inc. (U.S.)
- NexImmune (U.S.)
- Diabeloop SA (France)
- Admetsys (U.S.)
- Defymed (France)
- Pancreum, Inc. (U.S.)
- Beta Bionics Inc. (U.S.)
- Integra LifeSciences (U.S.)
SKU-